Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 12, 2008, Pages 4886-4891

  Baysarowich, Jennifer ^a   Koteva, Kalinka ^a   Hughes, Donald W ^b   Ejim, Linda ^a   Griffiths, Emma ^a   Zhang, Kun ^a   Junop, Murray ^a   Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Crystallography; Resistome; Ribosyltransferase; Rifampin

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL TOXIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN ADP RIBOSYL RIFAMPIN; RIFAMPICIN; RIFAMYCIN; TUBERCULOSTATIC AGENT;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTIBIOTIC RESISTANCE; ARTICLE; CATALYSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENOME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS AUREUS; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS; TUBERCULOSIS; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC VARIABILITY; GENETICS; KINETICS; METABOLISM; MICROBIOLOGICAL EXAMINATION; MUTATION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS); EUKARYOTA; MYCOBACTERIUM SMEGMATIS; STAPHYLOCOCCUS AUREUS;

ADP RIBOSE TRANSFERASES; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM SMEGMATIS; PROTEIN STRUCTURE, SECONDARY; RIFAMPIN; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; VARIATION (GENETICS);

EID: 42449159361     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711939105     Document Type: Article

References (46)

1. Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128:1037-1050.
2. Wright GD (2005) Bacterial resistance to antibiotics: Enzymatic degradation and modification. Adv Drug Deliv Rev 57:1451-1470.
3. Morisaki N, et al. (2000) Structures of ADP-ribosylated rifampicin and its metabolite: Intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756. J Antibiot (Tokyo) 53:269-275.
4. Imai T, et al. (1999) Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis. Microb Drug Resist 5:259-264.
5. Quan S, et al. (1999) ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene. Antimicrob Agents Chemother 43:181-184.
6. Quan S, Venter H, Dabbs ER (1997) Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 41:2456-2460.
7. Andersen SJ, Quan S, Gowan B, Dabbs ER (1997) Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance to rifampin by inactivating this antibiotic. Antimicrob Agents Chemother 41:218-221.
8. Tanaka Y, et al. (1996) Different rifampicin inactivation mechanisms in Nocardia and related taxa. Microbiol Immunol 40:1-4.
9. Morisaki N, et al. (1995) Structure determination of ribosylated rifampicin and its derivative: New inactivated metabolites of rifampicin by mycobacterial strains. J Antibiot (Tokyo) 48:1299-1303.
10. Dabbs ER, et al. (1995) Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 39:1007-1009.
11. Walsh CT (2006) Posttranslational Modification of Proteins (Roberts, Englewood, CO), pp 317-330.
12. Yates SP, Jorgensen R, Andersen GR, Merrill AR (2006) Stealth and mimicry by deadly bacterial toxins. Trends Biochem Sci 31:123-133.
13. Holbourn KP, Shone CC, Acharya KR (2006) A family of killer toxins: Exploring the mechanism of ADP-ribosylating toxins. FEBS J 273:4579-4593.
14. Ruf A, Rolli V, de Murcia G, Schulz GE (1998) The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol 278:57-65.
15. Mueller-Dieckmann C, Ritter H, Haag F, Koch-Nolte F, Schulz GE (2002) Structure of the ecto-ADP-ribosyl transferase ART2.2 from rat. J Mol Biol 322:687-696.
16. Reinert DJ, Carpusca I, Aktories K, Schulz GE (2006) Structure of the mosquitocidal toxin from Bacillus sphaericus. J Mol Biol 357:1226-1236.
17. Bell CE, Eisenberg D (1996) Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35:1137-1149.
18. Zhang RG, et al. (1995) The three-dimensional crystal structure of cholera toxin. J Mol Biol 251:563-573.
19. Li M, Dyda F, Benhar I, Pastan I, Davies DR (1996) Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: Implications for the activation process and for ADP ribosylation. Proc Natl Acad Sci USA 93:6902-6906.
20. Tsuge H, et al. (2003) Crystal structure and site-directed mutagenesis of enzymatic components from Clostridium perfringens iota-toxin. J Mol Biol 325:471-483.
21. Stein PE, Boodhoo A, Armstrong GD, Cockle SA, Klein MH, Read RJ (1994) The crystal structure of pertussis toxin. Structure (London) 2:45-57.
22. Schleberger C, Hochmann H, Barth H, Aktories K, Schulz GE (2006) Structure and action of the binary C2 toxin from Clostridium botulinum. J Mol Biol 364:705-715.
23. Han S, Arvai AS, Clancy SB, Tainer JA (2001) Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: Structural insights for recognition specificity and catalysis. J Mol Biol 305:95-107.
24. Floss HG, Yu TW (2005) Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 105:621-632.
25. Campbell EA, et al. (2001) Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
26. Van Scoy RE, Wilkowske CJ (1999) Antimycobacterial therapy. Mayo Clin Proc 74:1038-1048.
27. Ellis MW, Lewis JS, II (2005) Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 18:496-501.
28. Musser JM (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8:496-514.
29. Alexander DC, Jones JR, Liu J (2003) A rifampin-hypersensitive mutant reveals differences between strains of Mycobacterium smegmatis and presence of a novel transposon, IS1623. Antimicrob Agents Chemother 47:3208-3213.
30. Tribuddharat C, Fennewald M (1999) Integron-mediated rifampin resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 43:960-962.
31. Naas T, Mikami Y, Imai T, Poirel L, Nordmann P (2001) Characterization of In53, a class 1 plasmid- and composite transposon-located integron of Escherichia coli which carries an unusual array of gene cassettes. J Bacteriol 183:235-249.
32. Arlet G, Nadjar D, Herrmann JL, Donay JL, Lagrange PH, Philippon A (2001) Plasmid-mediated rifampin resistance encoded by an arr-2-like gene cassette in Klebsiella pneumoniae producing an ACC-1 class C beta-lactamase. Antimicrob Agents Chemother 45:2971-2972.
33. Houang ET, Chu YW, Lo WS, Chu KY, Cheng AF (2003) Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother 47:1382-1390.
34. Huang DB, DuPont HL (2005) Rifaximin - A novel antimicrobial for enteric infections. J Infect 50:97-106.
35. Rothstein DM, Shalish C, Murphy CK, Sternlicht A, Campbell LA (2006) Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 15:603-623.
36. Murphy CK, Karginova E, Sahm D, Rothstein DM (2007) In Vitro activity of novel rifamycins against Gram-positive clinical isolates. J Antibiot (Tokyo) 60:572-576.
37. Kim IH, et al. (2007) Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins. Bioorg Med Chem Lett 17:1181-1184.
38. Combrink KD, et al. (2007) New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett 17:522-526.
39. Hon WC, et al. (1997) Structure of an enzyme required for aminoglycoside resistance reveals homology to eukariotic protein kinases. Cell 89:887-895.
40. Wybenga-Groot L, Draker Ka, Wright GD, Berghuis AM (1999) Crystal structure of an aminoglycoside 6′-N-acetyltransferase:defining the GCN5-related N-acetyltransferase superfamily fold. Structure (London) 7:497-507.
41. Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y, Burley SK (1998) Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase. Cell 94:439-449.
42. m ratio of enzymatic modification of aminoglycosides by kanamycin acetyltransferase. Antimicrob Agents Chemother 25:479-482.
43. Otto H, Reche PA, Bazan F, Dittmar K, Haag F, Koch-Nolte F (2005) In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 6:139.
44. Holm L, Sander C (1993) Protein structure comparison by alignment of distance matrices. J Mol Biol 233:123-138.
45. Parikh SL, Schramm VL (2004) Transition state structure for ADP-ribosylation of eukaryotic elongation factor 2 catalyzed by diphtheria toxin. Biochemistry 43:1204-1212.
46. Zhou GC, et al. (2004) Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states. J Am Chem Soc 126:5690-5698.